Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines' Chief Medical Officer Fawzi Benzaghou to leave September 30, 2026

Neutral Impact 3 of 5 leadership Written later

Parabilis Medicines said its Chief Medical Officer, Fawzi Benzaghou, M.D., and the company mutually agreed on August 28, 2026 that he will transition out of the company effective September 30, 2026. He will receive severance benefits under his existing employment agreement, and the filing does not name a successor.

Key points

  • Departing officer: Fawzi Benzaghou, M.D., Chief Medical Officer
  • Agreement date: August 28, 2026; departure effective September 30, 2026
  • Severance benefits will be paid under the terms of his employment agreement; no amounts are disclosed in the filing

The filing

CompanyParabilis Medicines, Inc. (PBLS)
Form8-K, current report
Filed with the SECSep 2, 2026, 4:05 PM ET
Accession number0001193125-26-380171

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.